YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 17: Motorsport Games Inc. MSGM: This racing video games company has a Zacks Rank #1 and witnessed the Zacks Consensus Estima…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Movado Group, Inc. MOV: This watchmaking company has seen the Zacks Consensus Estimate for its current year earnings increasing 6% over the last 60 days. Movado Group…
Oil prices are on the rise once again as tensions continue to escalate in the Middle East. Markets have remained volatile for most of July and August, and the situation has worsened this month, with both the Dow and S&P 500 in the red. Inv…
Assembly Biosciences, Inc. – Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million c…
For Immediate Release Chicago, IL – September 8, 2026 – Stocks in this week's article are EuroDry Ltd. EDRY, RCM Technologies Inc. RCMT, Assembly Biosciences Inc. ASMB, Delcath Systems Inc. DCTH and National Energy Services Reunited Corp.…
U.S. stock markets ended August on a positive note after a mixed June and July. The Dow was up more than 1%, marking its fifth consecutive monthly winning streak. The S&P 500 and the Nasdaq Composite advanced 2.6% and 3.9%, respectively. B…
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 25: Liquidity Services, Inc. LQDT: This e-commerce company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for i…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Innovative Aerosystems, Inc. IA: This advanced avionic solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 6.9% over the…
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 21: Lumentum Holdings Inc. LITE: This optical and photonic products company has a Zacks Rank #1 and witnessed the Zacks Consens…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Mercury General Corporation MCY: This automobile-focused property and casualty insurer from the United States has seen the Zacks Consensus Estimate for its current ye…
Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support…
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. Th…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of…
(RTTNews) - Assembly Biosciences Inc. (ASMB), a biotechnology company, on Friday reported pricing of its underwritten registered offering. The company is offering 3,358,602 shares of common stock at $2.65 per share. In lieu of shares, the…
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on…
Assembly Biosciences, Inc. – Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candi…
Assembly Biosciences, Inc. – Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipate…
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recur…
Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The HSV programs include novel long-acting…
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--(BUSINESS WIRE)--G…
(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc.…
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study–…
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a int…
Company Logo The US Live Biotherapeutics Market offers growth opportunities driven by advancements in microbiome research and rising chronic diseases. Innovations are expanding treatment options for conditions like IBD and C. difficile inf…
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recur…
Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C. Wainwright reaffirmed its Buy rating and $50 price target on Assembly Biosciences (NASDAQ:ASMB) following the company’s p…
(RTTNews) - "Returns matter a lot. It's our capital," said Abigail Johnson, chief executive of Fidelity Investments - a powerful reminder that successful investing isn't just about owning stocks, but about understanding what you own and wh…
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will pa…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipRank…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Amazon.com(AMZN) to O…
Assembly Biosciences (ASMB) shares ended the last trading session 9.8% higher at $24.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.4% lo…
[Hepatitis B virus] Artur Plawgo/iStock via Getty Images Assembly Biosciences (NASDAQ:ASMB [https://seekingalpha.com/symbol/ASMB]) reported promising results from an early stage study of its experimental candidate, ABI-5366, a new treatmen…
Assembly Biosciences (NASDAQ:ASMB [https://seekingalpha.com/symbol/ASMB]) on Friday reported [https://seekingalpha.com/pr/20194856-assembly-biosciences-announces-pricing-of-175-million-in-equity-financings] the pricing of a public offering…
SOUTH SAN FRANCISCO - Assembly Biosciences, Inc. (Nasdaq:ASMB) announced Friday the pricing of an underwritten offering of approximately 6.6 million shares and warrants, raising about $130 million to support its viral disease therapeutic d…
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pri…